Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with123I-FP-CIT SPECT in healthy, male subjects

Journal of Nuclear Medicine

Volumn 53, Issue 7, 2012, Pages 1087-1090

  Koopman, Karin E ^a   La Fleur, Susanne E ^a   Fliers, Eric ^a   Serlie, Mireille J ^a   Booij, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

123I FP CIT; DAT; SERT; SPECT

Indexed keywords

N OMEGA FLUOROPROPYL 2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)NOTROPANE I 213; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DIENCEPHALON; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; MALE; MESENCEPHALON; NEUROIMAGING; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; CEREBELLUM; CORPUS STRIATUM; DIENCEPHALON; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MESENCEPHALON; PROTEIN BINDING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; YOUNG ADULT;

EID: 84863427169     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.102277     Document Type: Article

References (23)

1. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140.
2. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753-761. (Pubitemid 29210748)
3. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37:1129-1133. (Pubitemid 26329519)
4. 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48: 359-366.
5. 123I-PE2I. J Nucl Med. 2010;51:1885-1891.
6. 123I-FP-CIT SPECT study. Mov Disord. 2010;25:1853-1859.
7. Hesse S, Meyer PM, Strecker K, et al. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36:428-435.
8. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998;25:24-30.
9. 123I]β-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology. 2005;30: 996-1005.
10. 123I]beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982-994.
11. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27: 1533-1539. (Pubitemid 47301451)
12. 3H paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res. 1989;486:261-268.
13. 3H GRB 12935 binding to dopamine uptake sites in the human brain. J Neurochem. 1989;53:1400-1404.
14. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363-375. (Pubitemid 37489827)
15. 18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
16. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurements of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998;39:1500-1508. (Pubitemid 28459875)
17. 123I]ADAM in healthy young adults. Nucl Med Biol. 2006;33:185-191.
18. 123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men. Eur J Nucl Med Mol Imaging. 2010;37:1507-1511.
19. 123I-ADAM in the human brain. Psychiatry Res. 2009;172:38-43.
20. Maron E, Töru I, Hirvonen J, et al. Gender differences in brain serotonin transporter availability in panic disorder. J Psychopharmacol. 2011;25:952-959.
21. van Dyck CH, Malison RT, Seibyl JP, et al. Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT. Neurobiol Aging. 2000;21: 497-501. (Pubitemid 30621487)
22. Joensuu M, Tolmunen T, Saarinen PI, et al. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [123I] nor-beta-CIT SPECT imaging. Psychiatry Res. 2007;154:125-131. (Pubitemid 46275440)
23. 123I]β-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging. 2009;36:841-849.